Point of Care

// CONGEN develops and produces more than 5 million PCR beads

// customized assays according to customer requirements

More details

Research & Development

// over 20 years of experience in development and validation

// more than 300 completed development projects

More details

Clinical Diagnostics

// diagnostic detection kits developed in Germany
// unique-reproducible-sensitive

products

Food Analysis

// identification & quantification of relevant parameters
// fast-specific-secure

Products

Company

// founded in 1998
// in the heart of the science campus Berlin

Quality

Welcome to CONGEN

Since its founding in 1998, CONGEN Biotechnologie GmbH has been an innovative Berlin biotechnology company in the field of molecular DNA and RNA analysis. Our core competency is the development and application of real-time PCR methods for food- and water analyses, clinical and point-of-care diagnostics as well as personalised medicine in the context of companion diagnostics. Each detection method is developed by us in house and validated in respect of the requirements of standards, customers and/or the market.

Our products are marketed worldwide by us and our distribution partner R-Biopharm under the brand names SureFood^®, SureFast^®, RIDA^®GENE and RIDA^®PRECISION, which can be used on all common real-time PCR devices.

Food Analysis

CONGEN provides procedures in the field of food & feed analysis for the detection of allergenic substances, genetically engineered modifications, microorganisms and for animal and plant species identification. Our services are also being expanded into the field of veterinary diagnostics.

CONGEN Biotechnologie - Klinische Diagnostik

Clinical Diagnostics

Products in our clinical range include detection kits in the field of nosocomial and respiratory diagnostics, sexually transmitted diseases, stool diagnostics and periodontitis diagnostics. The detection methods we provide are produced in accordance with medical standards (DIN ISO 13485).

CONGEN Produkte - Personalisierte Medizin

Personalized Medicine

Personalized medicine aims to identify these sources and to adapt the treatment to the individual needs. Modern diagnostics enables physicians also to take into account the genetic, molecular and cellular specifics of a patient and to precisely determine the right therapy.

CONGEN Biotechnologie Forschung und Entwicklung

Research & Development

Design and validation of multiplexed real-time PCR methods based on customer requirements or unsolved analytical problems.

News & Events

Current developments, novel products, events and information from the field of science can be found on our news page.

Company

Since 1998 CONGEN Biotechnologie GmbH is located at the science campus Berlin Buch in the north of Berlin.

“Small enough to be flexible and fast,

big enough to meet every customer requirement.”

Leading in the development of real-time PCR based detection methods

Development of user-friendly solutions for your analytical problem

Specialist in design, validation and commercialization of multiplexed applications

Compliance with the highest quality standards is a matter of course

Aktuelles – Congen Biotechnologie GmbH

Insect Food Ingredient with Risks and Side Effects?

The EU Commission has approved two additional forms of edible insects for use in food. The new EU Regulation 2023/5 authorizes partially defatted powder of Acheta domesticus (domestic cricket) and EU Regulation 2023/58 authorizes the use of the frozen, pasty, dried...

Discontinuation of CONGEN ServiceLab from 2023

Developing detection systems based on nucleic acid analysis using PCR in the field of allergens, GMO and animal species and offering these to customers in the form of kits for their own use or as a service analysis, Matthias Kuhn and Steffen Mergemeier founded CONGEN...

5 million PCR beads for PoC applications

CONGEN supplies more than 5 million PCR beads since 2020 for PoC applications from various manufacturers The trend in the molecular diagnostic field towards all-in-one platforms has been ongoing for several years. All-in-one platform means that the nucleic acid...